Baseline characteristics of the 9369 patients in the RE-LY cohort according to study region
| Asia N=891 | Europe N=5024 | Latin America N=629 | North America N=2082 | Other N=743 | |
| Age, median (Q1–Q3) | 69.0 (63.0–75.0) | 72.0 (66.0–77.0) | 73.0 (67.0–78.0) | 74.0 (68.0–79.0) | 74.0 (69.0–79.0) |
| Female | 32.9% (293) | 36.9% (1855) | 40.1% (252) | 34.1% (711) | 40.0% (297) |
| BMI, median (Q1–Q3) | 24.3 (22.0–27.0) [3] | 28.1 (25.4–31.4) [1] | 27.9 (25.3–31.6) [0] | 29.0 (25.7–33.3) [3] | 28.4 (25.3–31.6) [0] |
| Systolic blood pressure, median (Q1–Q3) | 130.0 (120.0–140.0) [2] | 132.0 (120.0–145.0) [8] | 131.0 (120.0–144.0) [0] | 128.0 (118.0–140.0) [2] | 130.0 (120.0–143.8) [1] |
| Diabetes | 25.3% (225) | 20.4% (1024) | 16.2% (102) | 24.4% (509) | 29.5% (219) |
| Hypertension | 71.6% (638) | 78.7% (3954) | 82.0% (516) | 81.4% (1694) | 79.3% (589) |
| Smoker | 8.4% (75) | 8.6% (432) | 4.8% (30) | 6.3% (132) | 7.0% (52) |
| Permanent or persistent AF | 69.7% (621) [0] | 71.3% (3580) [0] | 87.3% (549) [0] | 5.2% (1147) [4] | 58.7% (436) [0] |
| Stroke/TIA | 29.4% (262) | 18.8% (944) | 14.9% (94) | 16.8% (349) | 23.4% (174) |
| Anaemia | 22.2% (198) | 10.2% (513) | 7.5% (47) | 14.0% (291) | 18.0% (134) |
| Congestive heart failure | 34.9% (311) [0] | 33.8% (1696) [0] | 33.9% (213) [0] | 16.0% (334) [1] | 21.1% (157) [0] |
| Myocardial infarction | 10.2% (91) | 17.2% (864) | 7.5% (47) | 19.6% (408) | 24.1% (179) |
| Peripheral arterial disease | 0.4% (4) [0] | 3.8% (193) [0] | 2.2% (14) [0] | 5.0% (105) [0] | 3.9% (29) [1] |
| CKD-EPI (mL/min/1.73 m2), median (Q1–Q3) | 70.7 (58.5–85.4) [0] | 65.5 (54.5–76.9) [75] | 57.9 (47.5–68.3) [0] | 64.2 (53.3–76.4) [8] | 63.1 (52.2–75.2) [8] |
| GDF-15 (ng/L), median (Q1–Q3) | 1606.0 (1181.5–2407.5) [76] | 1436.0 (1060.0–2067.0) [365] | 1545.0 (1142.2–2081.2) [19] | 1608.0 (1182.0–2332.0) [171] | 1744.5 (1231.5–2605.8) [87] |
| Haemoglobin (g/L), median (Q1–Q3) | 139 (127–151) [3] | 144 (134–154) [103] | 144 (134–155) [4] | 141 (131–151) [29] | 140 (128–150) [20] |
| NT-proBNP (ng/L), median (Q1–Q3) | 807.0 (400.5–1576.5) [3] | 837.0 (396.0–1477.0) [3] | 819.0 (453.0–1410.0) [8] | 748.0 (368.5–1354.0) [19] | 854.0 (372.5–1406.5) [8] |
| hs-cTnT (ng/L), median (Q1–Q3) | 10.8 (7.1–18.0) [39] | 12.2 (7.7–19.5) [385] | 12.9 (8.3–20.0) [21] | 12.0 (7.6–19.0) [121] | 13.8 (8.5–22.8) [84] |
| Outcomes | |||||
| Death | 66 (7%) | 341 (7%) | 54 (9%) | 104 (5%) | 42 (6%) |
| Major bleeding | 38 (4%) | 210 (4%) | 29 (5%) | 151 (7%) | 46 (6%) |
| Missing GDF-15 | 76 (9%) | 365 (7%) | 19 (3%) | 171 (8%) | 87 (12%) |
Number in brackets represents number of missings.
AF, atrial fibrillation; BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation; GDF-15, growth differentiation factor 15; hs-cTnT, high-sensitive cardiac troponin T; NT-proBNP, N-terminal pro B-type natriuretic peptide; Q, quartile; RE-LY, Randomized Evaluation of Long-Term Anticoagulation Therapy; TIA, transient ischaemic attack.